Table 2 Canonical pathways activated (z-score ≥2) and inhibited (z-score ≤ −2) generated by Ingenuity Pathway Analysis (IPA) in comparisons of the early and middle stages and late and middle stages.
Canonical Pathways | -log(p-value) | zScorea | Ratio | Molecules |
|---|---|---|---|---|
Middle vs. Early stages | ||||
iNOS Signaling | 2.10 | −2.00 | 0.133 | FOS, IFNGR1, IFNGR2, CALML5, JAK1, LBP |
CCR5 Signaling in Macrophages | 1.93 | −2.00 | 0.096 | GNAI1, FOS, GNG5, CCL5, CD3G, GNG7, CALML5, GNB1, CACNG1 |
IL-22 Signaling | 1.87 | −2.00 | 0.167 | IL10RB, AKT1, IL22RA1, JAK1 |
NRF2-mediated Oxidative Stress Response | 3.39 | −2.11 | 0.094 | SQSTM1, ABCC4, AKT1, UBE2E3, NQO2, HSPB8, MAP2K1, PPIB, FOS, AKR7A2, SOD2, CCT7, ACTB, PTPN11, CAT, EPHX1, AKR1A1, VCP, HERPUD1 |
Insulin Receptor Signaling | 1.51 | −2.11 | 0.075 | AKT1, PTPN11, PPP1R12A, PPP1CA, PPP1CB, PRKAR1B, JAK1, SCNN1A, MAP2K1, SYNJ1, PPP1R11 |
Oxidative Phosphorylation | 2.43 | −3.32 | 0.101 | SDHB, UQCRC1, NDUFA9, SDHA, NDUFV3, NDUFS6, ATPAF1, ATP5F1C, ATP5F1B, SDHC, NDUFS1 |
Late vs. Middle stages | ||||
Oxidative Phosphorylation | 2.18 | 2.50 | 0.119 | COX11, UQCRC1, SDHA, NDUFV3, NDUFAB1, NDUFS1, SDHB, UQCRQ, ATP5PO, NDUFA6, ATPAF1, ATP5F1C, SDHC |
Role of p14/p19ARF in Tumor Suppression | 1.46 | 2.45 | 0.133 | SENP3, FGFR1, UBTF, PTPN11, MDM2, TTF1 |
Endocannabinoid Cancer Inhibition Pathway | 1.57 | 2.32 | 0.095 | MAP2K5, GNAI1, FGFR1, SMPD2, MAP2K1, RHOA, PTPN11, CREB3, SPTLC1, TWIST2, PRKAR1B, DDIT3, VEGFB, CASP8, PRKAR2A |
